{"pageContent": "Context: Intermediate-risk prostate cancer consists of a highly heterogeneous group of patients. Owing to this heterogeneity and variable prognoses, it is challenging to provide uniform treatment recommendations for men in this group.", "metaData": {"source": "Optimum timing for image-based dose evaluation of 125I and 103PD prostate seed implants\nhttps://pubmed.ncbi.nlm.nih.gov/10571216/"}}